-
Lefradafiban
- names:
methyl 2-((3S,5S)-5-(((4'-(N-(methoxycarbonyl)carbamimidoyl)-[1,1'-biphenyl]-4-yl)oxy)methyl)-2-oxopyrrolidin-3-yl)acetate
- CAS号:
149503-79-7
MDL Number: - MF(分子式): C23H25N3O6 MW(分子量): 439.468
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | Lefradafiban |
| 英文别名 | Lefradafiban; BIBU-104; BIBU 104; BIBU104. |
| CAS号 | 149503-79-7 |
| Inchi | InChI=1S/C23H25N3O6/c1-30-20(27)12-17-11-18(25-22(17)28)13-32-19-9-7-15(8-10-19)14-3-5-16(6-4-14)21(24)26-23(29)31-2/h3-10,17-18H,11-13H2,1-2H3,(H,25,28)(H2,24,26,29)/t17-,18-/m0/s1 |
| InchiKey | PGCFXITVMNNKON-ROUUACIJSA-N |
| 分子式 Formula | C23H25N3O6 |
| 分子量 Molecular Weight | 439.468 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | Lefradafiban(CAS:149503-79-7):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | Lefradafiban, also known as BIBU-104, is a glycoprotein IIb/IIIa receptor antagonist potentially for the treatment of thrombosis. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol. 2004 Jan;56(1):43-5[1]PubMed PMID: 14980000. |
| [2]Doggrell SA. Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding? Drugs Today (Barc). 2001 Aug;37(8):509-531. PubMed PMID: 12743636. |
| [3] Nicholson NS, Abood NA, Panzer-Knodle SG, Frederick LG, Page JD, Salyers AK, Suleymanov OD, Szalony JA, Taite BB, Anders RJ. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001 May;21(3):211-26. PubMed PMID: 11301411. |
| [4] Akkerhuis KM, van Den Brand MJ, van Der Zwaan C, Peels HO, Suryapranata H, van Der Wieken LR, Stibbe J, Hoffmann J, Baardman T, Deckers JW, Simoons ML. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50. PubMed PMID: 11250974; PubMed Central PMCID: PMC1729676. |
| [5] McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. Health Technol Assess. 2000;4(30):1-95. Review. PubMed PMID: 11154975. |
6: Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J. 2000 Dec;21(24):2042-55. PubMed PMID: 11102255.7: Curtin R, Fitzgerald DJ. A cold start for oral glycoprotein IIb/IIIa antagonists. Eur Heart J. 2000 Dec;21(24):1992-4. PubMed PMID: 11102247.8: Drewe J, Narjes H, Heinzel G, Brickl RS, Rohr A, Beglinger C. Absorption of lefradafiban from different sites of the gastrointestinal tract. Br J Clin Pharmacol. 2000 Jul;50(1):69-72. PubMed PMID: 10886122; PubMed Central PMCID: PMC2014969.9: Lefradafiban. BIBU 104, BIBU 104XX. Drugs R D. 1999 May;1(5):383-4. PubMed PMID: 10566070.10: Storey RF, May JA, Wilcox RG, Heptinstall S. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. Thromb Haemost. 1999 Oct;82(4):1307-11. PubMed PMID: 10544919.1
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


